

# INTEGRATED PROTEINS LIMITED

City Point, 5th Floor, Opp. Town Hall, Jamnagar - 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566 Email ID: ps@arcadia.co.in/ipl.investors@gmail.com/ipl.complianceofficer@gmail.com

Website: www.integratedproteins.com

CIN: L15400GJ1992PLC018426

Ref. IPL/BSE/Regulation 33/December 2017 Results/Outcome

January 29, 2018

To.

The Department of Corporate Services,

BSE Limited,

Ground Floor,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001.

Kind Attn.: Mr. Marian D'Souza

Sub.: Outcome of Board Meeting held on 29th January, 2018.

Ref. (i) Script Code: 519606

(ii) Quarter [October-December] ended on 31st December, 2017.

Dear Sir,


With reference to above subject, we would like to inform you that the meeting of the Board of Directors of the Company was held today, i.e. Monday, 29th January, 2018, and the following main

1) The Board has received considered and approved the unaudited financial results for the quarter

We are enclosing herewith following documents:

- 1) A Certified copy of unaudited Financial Results for the quarter ended on 31st December, 2017
- Limited Review Report of Statutory Auditors of the company for that period.





# INTEGRATED PROTEINS LIMITED

City Point, 5th Floor, Opp. Town Hall, Jamnagar - 361 001, Gujarat, India Email ID: ps@arcadia.co.in/lpl.investors@gmail.com/ipl.complianceofficer@gmail.com

Phone: (0288) 2551901 Fax: (0288) 2552566

Website: www.irtegratedproteins.com

CIN: L15400GJ1992PLC018426

You are requested to take the same on your records.

Thanking You,

Yours faithfully,

For, Integrated Proteins Limited

(CS Bindiya A. Chhatbar)

Company Secretary & Compliance Officer

[Membership Number: A42359]

# **Doshi Maru & Associates**

Chartered Accountants



### **Limited Review Report**

Auditor's Report On Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement)

Regulations, 2015

To,

The Board of Directors Integrated Proteins Limited

CIN:-L15400GJ1992PLC018426

We have reviewed the accompanying statement of unaudited financial results of INTEGRATED PROTEINS LIMITED for the quarter ended 31st December, 2017 which are included in the accompanying "statement of Unaudited Financial Result for Quarter ended December 31, 2017" together with relevant notes thereon. The statement has been prepared by company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular dated July 5,2016, which has been initialed by us for identification Purposes. The statement is the responsibility of the company's management and has been approved by the Board of Directors. Further, the Management is also responsible to ensure that the accounting policies used in preparation of this statement in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants Of India.

# **Doshi Maru & Associates**

Chartered Accountants



Sarvesh A. Gohil

B.Com., F.C.A.

This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting other recognized accounting practices and policies has not disclosed the information required to disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Doshi Maru & Associates Chartered Accountants

FRN: 0112187W

wesh Ac Gohil

Membership No. 135782

Date: 29/01/2018 Place: Jamnagar

### INTEGRATED PROTEINS LIMITED

CIN:L24110MH1985PLC035078
Registered Office:Office No. 5, Mangalddeep CHS, opp. S.T. Joseph School Sector-4,Kalamboli, Navi Mumbai, Mumbai-4102018
Website: | Tel. No.: | Fax No.: | E-mail:

Statement of Unaudited Standalone Financial Results for the Quarter ended December 31, 2017

		Quarter Ended			YEAR TO DATE		( Amt. Rs. In Lakhs) YEAR ENDED
	Particulars	31.12.17 30.09.17		31,12,16	31.12.17	31,12.16	31-03-2017
A		01.10.17	200 P. D.		ALIEUTO ALIEUTO A		
B	Date of start of reporting quarter		01.07.17	01.10.16	01.04.17	01.04.16	01-04-2016
	Date of end of reporting quarter	31.12.17	30.09.17	31.12.16	31.12.17	31,12,16	31-03-2017
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue From Operations						
-	Net sales or Revenue from Operations		-	-		*:	
Ш	Other Income	5.16	4.46	5.15	14.12	15.89	20.46
	Total Revenue (I + II)	5.16	4.46	5.15	14.12	15.89	20.4
	Expenses						
	Cost of materials consumed		-			740	2
	Purchases of stock-in-trade			-			
	Changes in inventories of finished goods, work-in-progress and stock-in-trade			-		3.5	*
	Employee benefit expense	0.95	0.60	0.60	2.42	1.80	2,5
	Finance Costs		-				
	Depreciation and amortisation expense	0.72	0.72	0.70	2.16	2.20	2.92
(g	Other Expenses	0.78	0.47	1.44	4.67	6.02	6.6
	Total expenses	2.45	1.79	2.74	9.25	10.02	12.0
V	Profit (loss) before Exceptional and Extraordinary Items and tax (III-IV)	2.71	2.67	2.41	4.87	5.87	8.3
VI	Exceptional items	5-2	-		-		
VIII	Profit (loss) before Tax (VII-VIII)	2.71	2.67	2.41	4.87	5.87	8.3
X	Tax Expense						
(a)	Current Tax		2			227	3.5
(b)	Deferred Tax (Asset)/Liabilities				9-	790	-
XI	Net Profit/Loss for the period from Continuing Operations (IX-X)	2.71	2.67	2.41	4.87	5.87	4.78
	Profit (Loss) from Discontinuing Operations		-		7.0	*	-
XIII	Tax Expenses of Discontinuing Operations	***			100	190	
XIV	Net Profit (Loss) from Discontinuing Operartions after tax (XII-XIII)	-					
	Profit (Loss) for the period (XI+XIV)	2.71	2.67	2.41	4.87	5.87	4.78
XVI	Other Comprehensive Income						
	a . i). Amount of item that will not be reclassifed to profit or loss						
	ii). Income tax relating to items that will not be reclassifed to profit or loss						
XVI	b i). Item that will be reclassifed to profit or loss	19			-	24	
	ii). Income tax relating to items that will be reclassifed to profit or loss		4				
	Total Comprehensive income			786			(*)
	Total Comprehensive income [Comprising Profit for the Period ( After tax) and						
	Other comprehensive income ] (XV+XVII)	2.71	2.67	2.41	4.87	5.87	4.78
XVII	Details of equity share capital						
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	351.51	351.51	351.51	351.51	351.51	351.51
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX	Other Equities as per Balance Sheet		-		-		(98.49
XX	Earnings per share (Not Annualized for Quater ended)						
(a)							
()	Earnings per share Continuing Operation ( Not Annualised for Quarter ended )						
	Basic earnings per share before extraordinary items	0.08	0.08	0.07	0.14	0.17	0.14
	Diluted earnings per share before extraordinary items	80.0	0.08	0.07	0.14	0.17	0.14
(b)	Earnings per share Discontinuing Operation ( Not Annualised for Quarter ended )						
	Basic earnings per share after extraordinary items						-
	Diluted earnings per share after extraordinary items			- :		-	
	4.1						
(c)	Earnings per share ( Not Annualised for Quarter ended )						
171	Basic earnings per share before extraordinary items	0.08	0.08	0.07	0.14	0.17	0.14
	Diluted earnings per share before extraordinary items	0.08	0.08	0.07	0.14	0.17	0.14
_		0.00	0.00	0.07	0.14	0.17	0.1

### Notes:

- The Standalone financial results of Integrated Proteins Limited for the Quaterly and Financial year ended date have been reviewed by the Audit committee and subsequently approved and taken on record by the
- Board of Directors of the company at its meeting held on 29/01/2018
  The Company has single reportable business segment. Hence, no separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 -
- "Operating Segments".

  This Statement has been prepared in accordance with compines (indian Accounting Standrads) Rules, 2015 (Ind AS) prescribed under secation 133 of Compines Act, 2013 and other recoginesd accounting practices and policies to the extent applicable. Beginning 1st April 2017, the compay has for the first time adopted Ind AS with a transition date 1st April 2016.

PROTE

AMNAG

- The Ind As Copmpliant corresponding figure for quarter ended 31 December 2016, have not been subjected to limited review or audit. However, the company's, management has exercised necessary due diligence to ensure that the financial result provide a true and fair view of its affairs.
- The Statutory auditor of company have carried out a "Limited Review" of the above results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015.

6 The prior figures have been regrouped and reclassified wherever necessary.

For Integrated Proteins Limited

Date:- 29th January, 2018 Place:- Jamnagar

Arvind R Shah Director DIN:00094647 Reconcilliation of Statement of Profit and Loss as Previously Reported under GAAP to Ind-AS:

Particulars	For the Quarter ended December 31, 2016
Net Profit after tax as report under Previous GAAP	2.41
Ind AS Adjustment:Add/(loss)	
Total Income for the Quarter / Year Ended as per Ind AS	2.41
Other Comprehensive Income	
Total Comprehensive Income for the Quarter / Year Ended as per Ind AS	2.41

NIEGEN ON A STANDARMAN A STANDA

integrated Proteins Ltd.

Director.